H. Lundbeck A/S
Clinical trials sponsored by H. Lundbeck A/S, explained in plain language.
H. Lundbeck A/S
HLUN-B
COPENHAGEN
A pharmaceutical company focused on brain diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for teens with chronic migraines? Results expected Sep 2026 (estimated)
- New hope for rare hormone disorder: drug targets Out-of-Control cortisol Results expected Sep 2026 (estimated)
- New infusion drug hopes to tame rare hormone disorder Results expected Sep 2026 (estimated)
- Can a new drug play well with others? a trial puts it to the test Results expected Nov 2026 (estimated)
- New narcolepsy drug enters first human safety tests Results expected Feb 2027 (estimated)